Medicenna Therapeutics Insider Trading

Medicenna Therapeutics Corp. is a clinical-stage biotechnology company in the healthcare sector focused on developing and commercializing Superkines and empowered Superkines to treat cancer, inflammation, and immune-mediated diseases. Its lead clinical program is bizaxofusp, an interleukin-4 targeted therapy designed for patients with recurrent glioblastoma. The company is also developing MDNA11, an interleukin-2 therapy intended to activate anti-cancer immune cells while favoring activity over immunosuppressive regulatory T cells, and MDNA113, a bifunctional anti-PD-1-IL-2 superkine engineered to target and activate within tumors. In addition to these programs, Medicenna has preclinical assets that address conditions beyond oncology. MDNA209 is an IL-2/IL-15 antagonist being studied for autoimmune diseases including multiple sclerosis, graft versus host disease, and transplant rejection. MDNA413 is an IL-4/IL-13 antagonist being investigated for inflammatory conditions such as asthma, atopic dermatitis, and other allergic diseases. The company is headquartered in Toronto, Canada.